How long does MDA last?

The total duration of MDA via oral is 5 hours to 8 hours. Onset typically occurs within 30 minutes to 1.5 hours. Peak effects last 2.5 hours to 4 hours.

MDA — SubstanceWiki

Entactogen, stimulant, and psychedelic drug of the amphetamine family

3,4-Methylenedioxyamphetamine (MDA) is an entactogen, stimulant, and psychedelic drug of the amphetamine and MDxx families that is encountered mainly as a recreational drug. It is usually taken orally.

In terms of its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A receptor. It has a duration of 5 to 8hours or around 6hours typically.

MDA has a long history of psychotherapeutic and recreational use that predates that of MDMA, dating back to at least the mid-1960s. It has been described as the first entactogen. MDA has also been described as probably the most popular analogue of MDMA. In most countries, the drug is a controlled substance and its possession and sale are illegal.

How It Feels

The onset of MDA builds over sixty to ninety minutes, longer than MDMA, and arrives with a different accent. The first signs are physical: a warmth in the stomach and chest, a quickening pulse, and a peculiar body buzz that carries a psychedelic electricity absent from its methylated relative. As the come-up progresses, the visual field begins to shift. Colors deepen and saturate in ways that go beyond the mild enhancement of MDMA, and there is a growing sense that perception itself is being retuned.

As MDA reaches its full expression, the experience reveals its dual identity as both empathogen and psychedelic. The empathogenic component is robust: emotional warmth floods outward, social barriers dissolve, and there is a genuine, heartfelt openness that invites deep connection and honest conversation. But layered over this emotional landscape is a visual and cognitive intensity that MDMA does not approach. Closed-eye visuals are vivid and intricate, unfolding in patterns that are both geometric and organic. Open-eye distortions are pronounced: surfaces breathe, colors shift and flow, and the visual field has a rich, hallucinatory depth that can be genuinely immersive. The body buzzes with a persistent, almost electric energy. Jaw tension is severe. Body temperature climbs significantly.

At the peak, two to three hours in, MDA demands attention in a way that MDMA does not. The psychedelic component can produce moments of profound perceptual distortion: objects may seem to vibrate, faces can morph and shift, and the boundary between inner experience and outer reality becomes porous and negotiable. The emotional intensity is amplified by this psychedelic lens, making the experience both more profound and more challenging. Waves of euphoria alternate with moments of introspective gravity. The body is under significant strain: heart rate and blood pressure are elevated, sweating is profuse, and neurotoxic potential is higher than MDMA at equivalent doses.

The decline is gradual, unfolding over three to four hours as the psychedelic overlay fades before the empathogenic warmth. The total duration of five to eight hours is longer than MDMA. The comedown is more demanding: greater serotonergic depletion, more pronounced fatigue, and a deeper emotional flatness in the following days. Recovery may take two to four days. The heightened neurotoxicity and the intensity of the physical effects make MDA a substance that demands greater respect and more careful dosing than its reputation as psychedelic MDMA might suggest.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(16)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(11)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...

Detection Methods

Urine Detection

MDA (3,4-methylenedioxyamphetamine) is detectable in urine for 2 to 4 days following ingestion. MDA is both a psychoactive substance in its own right and a primary metabolite of MDMA, which complicates interpretation of positive results. Standard immunoassay-based urine screens for amphetamines or MDMA/ecstasy will typically detect MDA due to strong antibody cross-reactivity. The amphetamine backbone and methylenedioxy substitution are well-recognized by commercial immunoassay kits.

Blood and Serum Detection

Blood detection windows for MDA are approximately 12 to 24 hours after oral ingestion. Peak plasma concentrations occur 1 to 3 hours post-dose. MDA has a plasma half-life of approximately 8 to 12 hours, somewhat longer than MDMA, which contributes to its extended detection window. Quantitative blood analysis by LC-MS/MS or GC-MS can distinguish MDA from MDMA and other methylenedioxy compounds.

Standard Drug Panel Inclusion

MDA is detected by standard amphetamine immunoassays on 5-panel and extended drug screens. Most MDMA-specific assays also detect MDA with high sensitivity. On 10-panel and 12-panel screens that include MDMA as a specific target, MDA will reliably produce positive results. This makes MDA one of the more easily detected psychedelics on routine drug panels.

Confirmatory Methods

GC-MS and LC-MS/MS both reliably confirm MDA. Standard clinical confirmatory methods for amphetamines routinely include MDA as a reported analyte. Differentiation from MDMA is achieved through chromatographic separation and mass spectral fragmentation patterns. Hair follicle testing can detect MDA for up to 90 days with standard cutoff values.

Reagent Testing (Harm Reduction)

The Marquis reagent produces a dark purple to black reaction with MDA, confirming the methylenedioxy group. The Mecke reagent shows a dark blue to black reaction. The Simon reagent shows NO reaction with MDA (unlike MDMA, which produces a blue reaction), which is the key distinguishing test between the two compounds. The Mandelin reagent produces a dark brown to black reaction. MDA is distinguishable from MDMA through the Simon/secondary amine test.

Interactions

Substance	Status	Note
25x-NBOH	Dangerous	—
25x-NBOMe	Dangerous	—
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
MDMA	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined

Showing 82 key interactions out of 83 total.

History

MDA was originally synthesized by G. Mannish and W. Jacobson in 1910.

MDA was eventually patented as a cough suppressant by H. D. Brown in 1958, as an ataractic by Smith, Kline & French in 1960, and as an anorectic under the trade name "Amphedoxamine" in 1961. MDA began to appear on the recreational drug scene around 1967. In early 1968, the Bureau of Drug Abuse Control reported the seizure of over 1.4 kilograms of MDA and 11 kilograms of precursors from a clandestine laboratory in New York.

In 1992, a huge batch of pills known as "Snowballs" came into mass circulation in Europe, that unexpectedly contained MDA instead of MDMA. The batch unleashed a wave of extraordinary hallucinations across the UK and Europe that year, since the chemists had inaccurately dosed the pills with almost 200 mg of the active substance, which is generally enjoyed at lower amounts.

Several researchers, including Claudio Naranjo and Richard Yensen, have explored utilizing MDA in the field of psychotherapy. In 2010, Matthew Baggott and colleagues studied the ability of MDA to invoke mystical experiences and alter vision in healthy volunteers.

MDA, also known as 3,4-methylenedioxyamphetamine, is a synthetic molecule of the amphetamine family. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. MDA also contains substitutions at R3 and R4 of the phenyl ring with oxygen groups. These oxygen groups are incorporated into a methylenedioxy ring through a methylene chain. MDA shares this methylenedioxy ring with MDMA, MDAI and more obscure variants like MDEA or MMDA.

MDA acts as a releasing agent and reuptake inhibitor of the neurotransmitters known as serotonin, dopamine and norepinephrine. It also functions as a 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist and shows affinity for the TAAR1, α2A-, α2B-, α2C-adrenergic receptors and 5-HT1A and 5-HT7 receptors.

The effect on serotonin may explain the similar euphoric and empathogenic effects of the two compounds MDMA and MDA. However, MDA has a higher efficacy in stimulating the 5-HT2A receptor than MDMA; thus MDA tends to cause more psychedelic-like effects, such as visual geometry and hallucinations. While MDMA can also produce psychedelic-like visual effects, these are less pronounced than those of MDA or require a heavier dose to become apparent. It is worth noting that the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

While MDA is similar to MDMA, users report that MDA has more stimulant and psychedelic qualities and less intense entactogenic effects than MDMA. MDA is also considered to be less predictable than MDMA, with effects varying greatly from person to person.

Anecdotal evidence from people within the Psychonaut community who have tried MDA suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Harold Blauer died in January 1953 after being intravenously injected with 450 mg of MDA.

MDA is also known to be more neurotoxic when compared to substances such as MDMA or MDE.

It is strongly recommended that one use harm reduction practices when using this substance.

As with other stimulants,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to the psychedelic effects of MDA is built almost immediately after ingestion. However,repeated and heavy usage in a manner that varies between individuals. After that,37 days to be back at baseline (in the absence of further consumption). MDA presents cross-tolerance with Cross-all psychedelics and most stimulants, meaning that after the consumption of MDA all psychedelics and some stimulants will have a reduced effect.

Cocaine** - This combination may increase strain on the heart.
Amphetamine** - This combination may cause suicidal mania, paranoia, and hallucinations five days after cessation of long term amphetamine usage. This is caused by neural network disequilibrium likely related to the lack of calcium channel action by MDA.
Serotonin syndrome risk

Internationally, MDA is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.

Australia: MDA is a controlled substance.
Austria: MDA is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Canada: MDA is listed on the CSDA in Schedule I.
France: MDA is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.
Germany: MDA is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of September 1, 1984. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Russia: MDA is classed as a Schedule I prohibited substance.
Switzerland: MDA is a controlled substance specifically named under Verzeichnis D.
The Netherlands: MDA is illegal to possess, produce and sell in the Netherlands
United Kingdom: MDA is a class A drug.
United States: MDA is a Schedule I drug.
Responsible use
Entactogen
Amphetamine
MDMA
MDEA
6-APB
MDA (Wikipedia)
MDA (Erowid Vault)
MDA (PiHKAL / Isomer Design)
MDA (DrugBank)
Green, A.J., Mechan, A.O., Elliott, J.M., O'shea, E., & Colado, M.I. (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews, 55 3, 463-508. https://doi.org/10.1124/pr.55.3.3

Toxicity & Safety

Further information: Responsible use § Hallucinogens Anecdotal evidence from people within the Psychonaut community who have tried MDA suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Harold Blauer died in January 1953 after being intravenously injected with 450 mg of MDA.

MDA is also known to be more neurotoxic when compared to substances such as MDMA or MDE.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other stimulants, the chronic use of MDA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to the psychedelic effects of MDA is built almost immediately after ingestion. However, tolerance to the stimulant and entactogenic effects are built up after repeated and heavy usage in a manner that varies between individuals. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MDA presents cross-tolerance with all psychedelics and most stimulants, meaning that after the consumption of MDA all psychedelics and some stimulants will have a reduced effect.

Dangerous interactions

25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with MDA should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
Stimulants - MDA may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
Tramadol - Tramadol is known to lower the seizure threshold and combinations with stimulants may further increase this risk.
Cocaine - This combination may increase strain on the heart.
Amphetamine - This combination may cause suicidal mania, paranoia, and hallucinations five days after cessation of long term amphetamine usage. This is caused by neural network disequilibrium likely related to the lack of calcium channel action by MDA.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.
Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
SSRIs - Such as citalopram and sertraline
SNRIs - Such as tramadol and venlafaxine
5-HTP

Addiction Potential

Moderately addictive, similar to MDMA. Dopamine-releasing properties confer reinforcing potential. Tolerance develops with repeated use. Cross-tolerance with MDMA.

Overdose Information

Fatal overdose from MDA alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.

However, psychological emergencies can occur and require appropriate response:

Severe anxiety, panic, or psychotic episodes
Dangerous behavior due to impaired reality testing
Self-harm in the context of a distressing experience

Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.

MDA

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(16)

Tactile(1)

Cognitive & Perceptual Effects

Visual(11)

Pharmacology

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (3)

Tips (10)

Community Discussions (1)

See Also

Similar by Effects

References (8)

Frequently Asked Questions

Cognitive(24)

Transpersonal(2)